Edition:
India

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

66.44EUR
18 May 2018
Change (% chg)

€0.32 (+0.48%)
Prev Close
€66.12
Open
€66.22
Day's High
€66.89
Day's Low
€65.77
Volume
4,760,278
Avg. Vol
2,884,702
52-wk High
€89.43
52-wk Low
€62.88

Select another date:

Tue, May 1 2018

BRIEF-Regeneron And Sanofi To Lower Net Price Of Praluent For Express Scripts Patients

* REGENERON AND SANOFI TO LOWER NET PRICE OF PRALUENT® (ALIROCUMAB) INJECTION IN EXCHANGE FOR STRAIGHTFORWARD, MORE AFFORDABLE PATIENT ACCESS FOR EXPRESS SCRIPTS PATIENTS

Sanofi/Regeneron cut Praluent drug price in Express Scripts deal

May 1 Sanofi and Regeneron Pharmaceuticals said on Tuesday they had agreed to cut the price of their potent cholesterol drug, Praluent, under a deal with Express Scripts, the largest U.S. manager of prescription benefits.

Regeneron/Sanofi to cut price of heart drug in Express Scripts deal

May 1 Regeneron Pharmaceuticals and Sanofi will cut the net price of their expensive cholesterol drug for Express Scripts customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.

BRIEF-Sanofi: FDA To Conduct Priority Review Of Cemiplimab As Potential Treatment For Advanced Cutaneous Squamous Cell Carcinoma

* REG-SANOFI: FDA TO CONDUCT PRIORITY REVIEW OF CEMIPLIMAB AS A POTENTIAL TREATMENT FOR ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

UPDATE 2-Sanofi sees new acquisitions and drugs reviving growth

* Shares down 1.5 percent (Adds quotes from CEO, analyst comment, shares)

Sanofi Q1 hit by exchange rates, diabetes, growth not seen before second half

PARIS, April 27 French drugmaker Sanofi posted sluggish first-quarter profits on Friday, hurt by exchange rate effects and lower sales at its struggling diabetes and cardiovascular unit, and hinted at another difficult quarter ahead.

BRIEF-FDA Accepts For Review Sanofi's Supplemental Biologics License Application

* FDA ACCEPTS FOR REVIEW SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR 0.5 ML DOSE OF FLUZONE® QUADRIVALENT (INFLUENZA VACCINE) IN CHILDREN 6-35 MONTHS OF AGE

Boehringer's operating income up 20.7 percent on Sanofi deal

FRANKFURT, April 25 Boehringer Ingelheim, Germany's second-largest drugmaker, posted a gain in operating income of 20.7 percent to 3.5 billion euros ($4.27 billion) last year, boosted by the purchase of Sanofi's veterinary medicine.

UK bans Sanofi epilepsy drug without pregnancy prevention plan

LONDON A Sanofi drug for epilepsy and bipolar disorder linked to thousands of birth defects has been banned in Britain for use in women or girls of child-bearing age, unless they are on a special pregnancy prevention program.

UK bans Sanofi epilepsy drug without pregnancy prevention plan

LONDON, April 24 A Sanofi drug for epilepsy and bipolar disorder linked to thousands of birth defects has been banned in Britain for use in women or girls of child-bearing age, unless they are on a special pregnancy prevention programme.

Select another date: